NAMS - NASDAQ

NewAmsterdam Pharma Company N.V.

NAMS·NASDAQ

$32.11

+0.75%

HealthcareBiotechnology

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$3.75B

EPS-1.7500

P/E Ratio-18.35

Earnings Date08/05/2026

769.28M

Assets

-11%

3Y+61.0%

5Y+450.0%

10Y+450.0%

85.85M

Total Liabilities

-20%

3Y+77.0%

5Y+592.0%

10Y+592.0%

683.43M

Total Equity

-10%

3Y+59.0%

5Y+436.0%

10Y+436.0%

NewAmsterdam Pharma Company N.V. Funding & Solvency Profile

NAMS · NASDAQ

Current Assets

Cash & Cash Equivalents490.00M

Net Receivables23.15M

Inventory0.00

Other Current Assets1.32M

Total Current Assets676 M

Non-Current Assets

Property, Plant & Equipment568.00K

Goodwill & Intangible Assets407.00K

Long-Term Investments0.00

Other Non-Current Assets92.61M

Total Non-Current Assets93 M

Total Assets

769.28M

Financial Health Analysis

Current Ratio

7.88x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.13x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

590 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

88% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

NewAmsterdam Pharma Company N.V. Balance Sheet

NAMS • NASDAQ

NewAmsterdam Pharma Company N.V. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	490M	771.7M	340.5M	467.7M	60.4M	1.4M
Short-Term Investments	146.2M	62.4M	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	636.2M	834.2M	340.5M	467.7M	60.4M	1.4M
Net Receivables	23.2M	21.3M	1.9M	0.0	0.0	0.0
Other Receivables	23.2M	21.3M	1.9M	0.0	0.0	0.0
Prepaids	15M	7.9M	4.5M	8.2M	1.7M	503.7K
Other Current Assets	1.3M	0.0	0.0	2.1M	4.9M	0.0
Total Current Assets	675.7M	863.4M	346.8M	478M	67M	1.9M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	568K	673K	101K	154K	216.1K	0.0
Intangible Assets	407K	534K	170K	208K	0.0	0.0
Goodwill & Intangible Assets	407K	534K	170K	208K	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	138M
Other Non-Current Assets	92.6M	0.0	35K	156K	816.6K	0.0
Total Non-Current Assets	93.6M	1.2M	306K	518K	1M	138M
Total Assets	769.3M	864.6M	347.1M	478.5M	68M	139.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	9M	4.7M	16.9M	11.9M	7.1M	162.5K
Accounts Payable	9M	4.7M	16.9M	11.9M	7.1M	162.5K
Accrued Expenses	0.0	4.9M	8M	6.1M	4.1M	0.0
Short Term Debt	136K	246K	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	0.0	60K	66K	60.3K	0.0
Deferred Revenue	4M	6M	8.9M	0.0	0.0	0.0
Other Current Liabilities	72.7M	91M	16M	18M	0.0	74K
Total Current Liabilities	85.8M	106.9M	49.9M	36.1M	11.2M	236.5K
NON-CURRENT LIABILITIES
Long Term Debt	66K	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	1M	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	7.8M	12.3M	0.0	12.2M
Total Non-Current Liabilities	66K	202K	8.8M	12.4M	126.2K	12.2M
Capital Lease Obligations	0.0	202K	60K	126K	186.5K	0.0
Total Liabilities	85.9M	107.1M	58.7M	48.4M	11.4M	12.4M
SHAREHOLDERS' EQUITY
Common Stock	14.3M	13.4M	10.2M	10.1M	128.5K	122.5M
Additional Paid-In Capital	1.4B	0.0	590.8M	555.6M	95.3M	5M
Retained Earnings	-762.4M	0.0	-317M	-140M	-39.4M	41.5K
Accumulated Other Comprehensive Income/Loss	4.8M	4.5M	4.4M	4.4M	672.1K	0.0
Other Total Stockholders' Equity	0.0	739.6M	0.0	0.0	0.0	0.0
Total Stockholders' Equity	683.4M	757.5M	288.4M	430.1M	56.6M	127.5M
Total Equity	683.4M	757.5M	288.4M	430.1M	56.6M	127.5M
SUMMARY
Total Liabilities & Equity	769.3M	864.6M	347.1M	478.5M	68M	139.9M
Total Investments	146.2M	62.4M	0.0	0.0	0.0	138M
Total Debt	202K	448K	60K	126K	186.5K	0.0
Net Debt	-489.8M	-771.3M	-340.4M	-467.6M	-60.2M	-1.4M
Shares Outstanding	116,903,979	116,903,979	116,903,979	116,903,979	116,903,979	116,903,979

SEC Filings

NAMS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 03, 2026	June 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 24, 2026	April 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 02, 2026	March 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 18, 2026	February 18, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 18, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 09, 2026	January 09, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 05, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 87 filings

Related Guides

Blog Categories

Continue your NAMS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.